Ali Omar, Wharton John, Gibbs John Simon Russell, Howard Luke, Wilkins Martin Russell
Imperial College London, Experimental Medicine & Toxicology, Hammersmith Hospital, London, UK.
Expert Opin Investig Drugs. 2007 Jun;16(6):803-18. doi: 10.1517/13543784.16.6.803.
Pulmonary arterial hypertension is characterised by increased pulmonary vascular resistance due to increased vascular tone and structural remodelling of pulmonary vessels. The therapies that are in use so far have been developed to correct endothelial dysfunction and reduce vasomotor tone. These treatments have a limited effect on the remodelling process and, increasingly, the focus is turning to potent strategies for inhibiting vascular proliferation and promoting vascular apoptosis. Multiple novel targets have been uncovered over the last 5 years and several are now in early clinical trials. At present, it is clear that there is no single treatment for the condition. Although this is the case, studies are investigating the role of combining therapies that are already established.
